Dual mTOR Inhibition Is Required to Prevent TGF-β-Mediated Fibrosis: Implications for Scleroderma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Dual mTOR Inhibition Is Required to Prevent TGF-β-Mediated Fibrosis: Implications for Scleroderma

Published:2015-11 Issue:11 Volume:135 Page:2873-2876
ISSN:0022-202X
Container-title:Journal of Investigative Dermatology
language:en
Short-container-title:Journal of Investigative Dermatology

Author:

Mitra Anupam,Luna Jesus I.,Marusina Alina I.,Merleev Alexander,Kundu-Raychaudhuri Smriti,Fiorentino David,Raychaudhuri Siba P.,Maverakis Emanual

Publisher

Elsevier BV

Subject

Cell Biology,Dermatology,Molecular Biology,Biochemistry

Reference14 articles.

1. New developments in fibroblast and myofibroblast biology: implications for fibrosis and scleroderma;Abraham;Curr Rheumatol Rep.,2007

2. Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin;Bhagwat;Mol Cancer Ther,2011

3. Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities;Bhattacharyya;Nat Rev Rheumatol,2012

4. 1,25-Dihydroxyvitamin D3-3-bromoacetate, a novel vitamin D analog induces immunosuppression through PI3K/Akt/mTOR signaling cascade;Datta-Mitra;Int Immunopharmacol,2013

5. Efficacy of rapamycin in scleroderma: a case study;Fried;Lymphat Res Biol,2008

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current state of signaling pathways associated with the pathogenesis of idiopathic pulmonary fibrosis;Respiratory Research;2024-06-17

2. Redox Pathogenesis in Rheumatic Diseases;ACR Open Rheumatology;2024-04-25

3. Metabolic control of pathogenesis in autoimmune diseases;The Rose and Mackay Textbook of Autoimmune Diseases;2024

4. Optimization of mTOR Inhibitors Using Property-Based Drug Design and Free–Wilson Analysis for Improved In Vivo Efficacy;ACS Medicinal Chemistry Letters;2023-10-25

5. Endometriosis-Associated Ovarian Carcinomas: How PI3K/AKT/mTOR Pathway Affects Their Pathogenesis;Biomolecules;2023-08-16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3